JP2023548758A5 - - Google Patents
Info
- Publication number
- JP2023548758A5 JP2023548758A5 JP2023521661A JP2023521661A JP2023548758A5 JP 2023548758 A5 JP2023548758 A5 JP 2023548758A5 JP 2023521661 A JP2023521661 A JP 2023521661A JP 2023521661 A JP2023521661 A JP 2023521661A JP 2023548758 A5 JP2023548758 A5 JP 2023548758A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- polypeptide
- enpp1
- enpp3
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089515P | 2020-10-08 | 2020-10-08 | |
| US63/089,515 | 2020-10-08 | ||
| US202163165650P | 2021-03-24 | 2021-03-24 | |
| US63/165,650 | 2021-03-24 | ||
| US202163248339P | 2021-09-24 | 2021-09-24 | |
| US63/248,339 | 2021-09-24 | ||
| PCT/US2021/054216 WO2022076848A1 (en) | 2020-10-08 | 2021-10-08 | Liver specific production of enpp1 or enpp3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548758A JP2023548758A (ja) | 2023-11-21 |
| JP2023548758A5 true JP2023548758A5 (https=) | 2024-10-16 |
Family
ID=81126156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521661A Pending JP2023548758A (ja) | 2020-10-08 | 2021-10-08 | Ｅｎｐｐ１またはｅｎｐｐ３の肝臓特異的生成 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240148907A1 (https=) |
| EP (1) | EP4225927A4 (https=) |
| JP (1) | JP2023548758A (https=) |
| AU (1) | AU2021356692A1 (https=) |
| CA (1) | CA3195071A1 (https=) |
| TW (1) | TW202229557A (https=) |
| WO (1) | WO2022076848A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3231858A1 (en) * | 2021-09-24 | 2023-03-30 | Inozyme Pharma, Inc. | Lyophilized enpp1 polypeptide formulations and uses thereof |
| CN119242712A (zh) * | 2024-09-27 | 2025-01-03 | 南京师范大学 | 特异性靶向骨骼肌细胞的携带miRNA-486基因的腺相关病毒载体、药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1736553A1 (en) * | 2005-06-17 | 2006-12-27 | Centre National De La Recherche Scientifique | ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| US9169492B2 (en) * | 2010-02-05 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2014126965A2 (en) * | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| EP3377105A4 (en) * | 2015-11-20 | 2019-04-24 | Yale University | COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH |
| CA3126839A1 (en) * | 2019-01-18 | 2020-07-23 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of enpp1 or enpp3 |
-
2021
- 2021-10-08 CA CA3195071A patent/CA3195071A1/en active Pending
- 2021-10-08 AU AU2021356692A patent/AU2021356692A1/en active Pending
- 2021-10-08 WO PCT/US2021/054216 patent/WO2022076848A1/en not_active Ceased
- 2021-10-08 JP JP2023521661A patent/JP2023548758A/ja active Pending
- 2021-10-08 EP EP21878635.8A patent/EP4225927A4/en not_active Withdrawn
- 2021-10-08 TW TW110137622A patent/TW202229557A/zh unknown
-
2023
- 2023-04-07 US US18/297,228 patent/US20240148907A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2653444C2 (ru) | Композиции вектора aav и способы переноса генов в клетки, органы и ткани | |
| EP3235827B1 (en) | Aav virions with decreased immunoreactivity and uses therefor | |
| KR20230082614A (ko) | 유전자 요법을 안구 전달하기 위한 아데노-연관 바이러스 | |
| JP2022544004A (ja) | 操作された核酸調節エレメントならびにその使用方法 | |
| KR20210021310A (ko) | 코돈-최적화된 산 알파-글루코시다제 발현 카세트 및 이를 사용하는 방법 | |
| KR20170116055A (ko) | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 | |
| JP2021500071A (ja) | ヒト翻訳後修飾ｖｅｇｆ−ｔｒａｐによる眼疾患および転移性大腸がんの処置 | |
| EP3952920A1 (en) | Hybrid promoters for muscle expression | |
| EP3956354A1 (en) | Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases | |
| JP2023548758A5 (https=) | ||
| JP2023537070A (ja) | 小胞を標的とするタンパク質及びその使用 | |
| JP2022517435A5 (https=) | ||
| JP2022517435A (ja) | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 | |
| WO2022222869A1 (zh) | 重组腺相关病毒及其应用 | |
| US20180163229A1 (en) | Novel recombinant adeno-associated virus capsids containing a designed ankyrin repeat protein (darpin) or fragment thereof | |
| US20130287739A1 (en) | Serca2 therapeutic compositions and methods of use | |
| AU2021356692A1 (en) | Liver specific production of enpp1 or enpp3 | |
| EP4334454A2 (en) | Novel aav vectors and methods and uses thereof | |
| US20250288697A1 (en) | Vectorized anti-tnf-alpha inhibitors for ocular indications | |
| TW202426479A (zh) | Apoe基因療法 | |
| JP2024528997A (ja) | 放射線誘発性唾液機能低下を予防するためのａｑｐ１遺伝子療法 | |
| KR20230082613A (ko) | Cns 또는 근육 전달을 위한 재조합 아데노-연관 바이러스 | |
| EP4694904A2 (en) | Targeting aav capsids, methods of manufacturing and using same | |
| WO2026057767A1 (en) | Use of split intein for the treatment of abca3-associated disease | |
| WO2024254232A2 (en) | Two-plasmid system for aav vector particle production |